SALT LAKE CITY--(BUSINESS WIRE)--Great Basin Scientific, Inc. (NASDAQ: GBSN, GBSNU), a molecular diagnostics company, announced today the European Patent Office has issued a notice to allow for application (#09711952.3) for the Company’s on-chip amplification technology, currently patented in the U.S.
This newly allowed patent further enhances protections for the Company's patent portfolio, and follows the U.S. patent (8,637,250, issued Jan. 28, 2014) for the same technology for point-of-care isothermal amplification and detection of polynucleotides on the surface of modified silicon chips. This patent drives technology behind future simplification of the chip technology, fully integrating sample preparation, amplification, and detection to provide faster results at a lower cost, asserts Great Basin.
“Protecting our intellectual and technological assets in competitive markets is critical to building upon our accomplishments, which we feel further emphasizes our leadership team’s ability to execute against our business objectives and sets us apart in the molecular diagnostic space,” said Great Basin co-founder and Chief Executive Officer, Ryan Ashton. “This designation continues our momentum in providing inexpensive, easy-to-use low-plex and multi-plex tests for our growing customer base.”
About Great Basin Scientific
Great Basin Scientific is a molecular diagnostics company that commercializes breakthrough chip-based technologies. The Company is dedicated to the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases. The Company’s vision is to make molecular diagnostic testing so simple and cost-effective that every patient will be tested for every serious infection, reducing misdiagnoses and significantly limiting the spread of infectious disease. More information can be found on the company’s website at www.gbscience.com.
This press release includes forward-looking statement regarding events, trends and business prospects, which may affect our future operating results and financial position. Forward-looking statements involve risk and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risk and uncertainties include, but are not limited to: (i) our limited operating history and history or losses; (ii) our ability to develop and commercialize new products and the timing of commercialization; (iii) our ability to obtain capital when needed; and (iv) other risks set forth in the Company’s filings with the Securities and Exchange Commission, including the risks set forth in the company’s Annual Report on Form 10-K for the year ended December 31, 2014. These forward-looking statements speak only as of the date hereof and Great Basin Scientific specifically disclaims any obligation to update these forward-looking statements, except as required by law.